Luteinising hormone releasing hormone (LHRH) analogues are routinely used in the treatment of patients with advanced prostate cancer. This randomised crossover trial was conducted to compare patient comfort and tolerability between two commonly used LHRH analogues: goserelin acetate and leuprorelin acetate. A total of 50 patients were randomised into two groups, each receiving 6-monthly injections of leuprorelin acetate (a liquid presentation) and goserelin acetate (a depot pellet) and crossing over between treatments. Patients completed a simple visual analogue score for the discomfort felt from the injections. An analysis of variance model was used, and the results found that patients do tolerate leuprorelin acetate (0.589) better than goserelin acetate (1.343) (Po0.001, CI ¼ 95%).
Introduction
Prostate cancer is the most common male cancer in Western countries and the second most common cause of cancer death. The past 20 years have seen a 50% increase in the number of new cases diagnosed each year. With the age of the population continuing to rise, it looks certain that the incidence of prostate cancer will increase. 1 For patients with advanced prostate cancer, luteinising hormone releasing hormone (LHRH) analogues such as leuprorelin acetate or goserelin acetate are most often used. LHRH analogues are recommended by the British Association of Urological Surgeons (BAUS) as an alternative to orchidectomy in the first-line treatment of metastatic prostate cancer. 2 The analogues work by suppressing the action of serum testosterone, and have been shown to produce a temporary remission of tumour growth in about 85% of patients. Treatment is given by a monthly or 3-monthly injection into the skin or abdomen. Often the treatment is combined with another type of anti-androgen therapy. Occasionally, other drugs will be used in the treatment, and severe pain in the bones often responds dramatically to treatment with radiotherapy.
While the efficacy of the preparations is similar, it is the administration of the medication that differs. Goserelin acetate is given subcutaneously as a depot pellet in the abdomen via a 16 Ch needle, often with the need for a local anaesthetic. Leuprorelin acetate, however, is given as a liquid subcutaneously or intramuscularly through a smaller needle (23 Ch or 21 Ch). While both are well-established treatments, patient acceptability of these different forms of administration has not been assessed. This study was undertaken to investigate whether there is a difference in patient tolerability between the two methods of administration.
Methods
Patients who were undergoing LHRH analogue therapy, for prostate cancer, were recruited from the urology clinic at The Royal Gwent Hospital, Newport. The patients were randomised into two groups, both receiving a run-in period of 8 weeks goserelin acetate. This was to allow the patients to normalise to the injection without a local anaesthetic. Four subsequent injections were given to all patients. Group A received two leuprorelin acetate injections followed by two goserelin acetate injections and Group B received two goserelin acetate injections followed by two leuprorelin acetate injections. All the injections were administered monthly/4-weekly and without a local anaesthetic. The same nurse gave the injections.
At each visit, the patients recorded their experiences on a questionnaire including a simple Visual Analogue Symptom Scale (ranging from 0 ¼ no discomfort to 10 ¼ worst discomfort) to assess the level of discomfort experienced. Their discomfort was recorded both immediately after the injection and also 2 h later.
An analysis of variance model was used to evaluate any treatment effects, with the between-patient factors of sequence LG (Group A) and GL (Group B) and patient and the within-patient factors of periods 1 and 2 and treatment being fitted. Due to the discrete nature of the data, a supportive nonparametric Wilcoxon matchedpairs rank sum test was also performed.
Results
A total of 50 patients were entered into the study, with 25 patients being randomised into each group. Of the patients, four were staged as having T2 disease, 26 as T3, and 20 as T4. The mean age of the patients participating in the trial was 73 years (range 48-89). The length of time diagnosed with prostate cancer varied from 0 to 134 months (mean 20). The PSA levels on entering the study varied from 0.2 to 850 mg/l (mean 81.8 mg/l). While 40% (20) of the patients had received previous treatment for prostate cancer, only 26% (13) had previously received LHRH analogues.
Of the 50 patients randomised, 42 (84%) completed the 6-month study period and were included in the analysis. Of the eight patients who withdrew, five were from Group B and three were from Group A. The reasons for withdrawal were: wished GP to give injection rather than continue at hospital (3); reluctance to have goserelin acetate without local anaesthetic (2); wanted surgical castration (1); change in family circumstances, which no longer enabled continuation (1); and a reluctance to change from usual treatment (goserelin acetate) (1).
The data from doses one and two were not used in the analysis but are summarised in Table 1 . This shows that both groups had similarly matched scores for discomfort in the run-in period. For the purposes of the summary and analysis, the means of doses 3-4 (period 1) and 5-6 (period 2) were used for each period. The results of these scores are summarised in Figure 1 .
Of the 25 patients randomised to Group A, 24 patients provided data for period 1 and 20 patients for period 2. Similarly, of the 25 randomised to Group B, 21 patients provided data for period 1 and 21 patients for period 2. Table 2 shows a summary of the results of the analysis of variance. A difference (95% CI) between the treatment groups of 0.75 (0.42, 1.09) was observed for the pain discomfort scores immediately after injection, in favour of the leuproprelin acetate group. This difference was statistically significant (Po0.001). Discomfort scores 2 h after injection also showed leuprorelin acetate injections to be less painful, but this result was not found to be statistically significant. The results of the supportive analysis were consistent with those given above. A subgroup analysis confirmed the same trend in all T-stage groups.
Conclusion
The results of the study found that patients do tolerate leuprorelin acetate better than goserelin acetate, with a statistically significant difference being observed between the patients' discomfort immediately after the 
